Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy males~2. Body mass index (BMI) =18.5 to =29.9 kg/m2~Exclusion criteria:~1. Any clinically relevant abnormal finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance~2. Any evidence of a clinically relevant previous or concomitant disease as judged by the investigator.~3. Chronic or relevant acute infections. A negative result for Human Immunodeficiency Virus, Hepatitis B and Hepatitis C testing is required for participation.~4. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)~5. Intake of prescribed or over-the-counter drugs with a long half-life (\>24 hours) within at least one month or less than 5 half-lives of the respective drug prior to administration or during the trial~6. Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)~7. Inability to refrain from smoking during days of confinement at the study center~8. Alcohol abuse (average more than 30 g/day)~9. Current drug abuse

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BI 695501 (Type: EXPERIMENTAL): Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
- adalimumab - US (Type: ACTIVE_COMPARATOR): Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
- adalimumab - EU (Type: ACTIVE_COMPARATOR): Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab

Based on this trial design, predict the completion outcome and termination type (if applicable).